Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.65 +0.52 (+2.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
Is Pfizer Stock Ready to Bounce Back?
The stock won't stay down forever. 
Via The Motley Fool
Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling
Via Benzinga
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
3 Dividend Stocks to Double Up On Right Now
How does a 5.7% dividend yield sound? 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These cheap stocks might not be cheap for too much longer. 
Via The Motley Fool
Why Pfizer Stock Slumped on Friday
Investors were cautiously pessimistic about the latest news coming out of the company's lab. 
Via The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
The company is now considering whether it needs to change up the vaccine to pass muster. 
Via Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
Via Benzinga
Exposures COVID-19
Market Whales and Their Recent Bets on PFE Options
Via Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting... 
Via Benzinga
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection... 
Via Benzinga
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets. 
Via InvestorPlace
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth. 
Via InvestorPlace
3 Top Investing Opportunities During Stock Market Chaos
These stocks look like some of the top investing opportunities to buy on the recent dip that has the broader investment class worried. 
Via InvestorPlace
7 Divine Dividend Stocks to Buy for Another Market Crash
Dividend stocks have proved remarkably resilient even during severe market downturns, making them perfect additions to your portfolio. 
Via InvestorPlace
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
Exposures COVID-19
What's Going On With Pfizer Shares Tuesday?
Pfizer reported top-line results of ABRYSVO, a novel vaccine, for respiratory syncytial virus (RSV) in immunocompromised adults. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
3 Undervalued Low-Beta Stocks to Buy to Protect Yourself From Volatility
These are the undervalued low-beta stocks that have robust cash flow potential coupled with steady top-line growth. 
Via InvestorPlace
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
Pfizer's Respiratory Syncytial Virus Vaccine Data Shows Promise In Subgroup Of Younger Immunocompromised Patients
Pfizer's Abrysvo vaccine shows strong response against RSV in immunocompromised adults. 
Via Benzinga
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS